STAT+: CytoDyn has data on its highly touted experimental Covid treatment. Investors and patients don’t
CytoDyn CEO Nader Pourhassan has been uncharacteristically quiet this week about a completed clinical trial involving patients with severe, life-threatening cases of Covid-19.
It’s uncharacteristic because Pourhassan has not been shy in touting the potential of CytoDyn’s only drug, an experimental antibody called leronlimab — not currently approved to treat anything. He has claimed leronlimab is capable of effectively treating HIV, 22 different types of cancer, fatty liver disease, multiple sclerosis, and Alzheimer’s disease, among other ailments.
Continue to STAT+ to read the full story…
